Eli Lilly and Almirall report promising results from phase III atopic eczema study

A collaboration between Spanish firm Almirall and US-based Eli Lilly has so far resulted in positive results from three of five global phase III studies with the drug lebrikizumab. Marketing rights for Europe and the rest of the world have been split between the firms.
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
by ulrich quistgaard, translated by daniel pedersen

Pharmaceutical giant Eli Lilly and Spanish dermatology company Almirall have come together to develop a treatment for atopic dermatitis, also known as atopic eczema.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading